Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Corporate Communications
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
中
中
中
Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Corporate Communications
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
Our Science
>
Our Science
>
Poster and Presentation
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Poster and Presentation
2016 ADA Poster
Clinical Proof of Concept (POC) of Glucokinase Activator HMS5552 Achieved in Chinese T2DM Patients: HbA1c Reduction of 1.22% with 100% Response Rate and Improved β-cell Function
Read More
2016 Chinese Pharmacological Society
Prediction of HMS5552 human pharmacokinetics using Allometric Scaling, IVIVE,Css-MRT and PBPK Modeling Methods (2016 中国药理学会定量药理学专业委员会年会)
Read More
2015 ADA Poster
Clinically Differentiated Glucokinase Activator HMS5552: Effective Control of 24-Hour Glucose and Improvement of β Cell Function in T2DM Patients
Read More
2015 ADA Poster
A Novel Dual Pancreatic and Hepatic Acting Glucokinase Activator, HMS5552: Phase I Studies in Healthy Subjects and T2DM Patients
Read More
2015 February/ Intractable & Rare Diseases Research
Fragile X syndrome as a rare disease in China - Therapeutic challenges and opportunities.
Read More
2015 CDS
葡萄糖激酶激活剂HMS5552对2型糖尿病大鼠肝组织中葡萄糖激酶的调节作用 (2015 CDS)
Read More
<<
<
1
2
3
4
5
>
>>
上一页
下一页
About Us
Company Overview
Company History
Leadership Team
Portfolio Advisory Board
Senior Scientific Advisory Board
Partner
Media center
Research & Development
Inovation
Pipeline
Dorzagliatin
mGluR5
Company Publications
Peer Reviewed Publications
Investor Relations
Corporate Governance
Financial Report
Announcements & Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock information
Media
Company News
Media Releases
Video
Careers
Culture
Join Us
Product
HuaTangNing(华堂宁®)
Subscribe Email
Focus Us
Copyright © 2024 Hua Medicine (Shanghai) Co., Ltd. 互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备14036654号-1
沪公网安备 31011502013809号
Privacy Statement
Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our
privacy statement
.
Accept
x